AMD-Mamba:一种表型感知多模式框架,用于稳健的AMD预后
Puzhen Wu1, Mingquan Lin2, Qingyu Chen3
1Department of Population Health Sciences, Weill Cornell Medicine, New York, NY 10022, USA.
Machine learning in medical imaging. MLMI (Workshop)
|January 13, 2026
概括
我们开发了AMD-Mamba,一种新的AI框架,以及一种新的生物标志物来预测与年龄相关的黄斑变性 (AMD) 的进展. 该工具整合了成像,遗传和人口统计数据,以便更早地检测高风险患者.
科学领域:
- 眼科和人工智能的人工智能
- 生物医学信息学 生物医学信息学
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是不可逆转的视力丧失的主要原因,需要准确的预后及时干预.
- 当前的预后方法往往侧重于有限的局部特征,可能缺少关键的疾病进展模式.
研究的目的:
- 介绍AMD-Mamba,这是一个用于AMD预后的新型多模式框架.
- 开发和验证一个新的AMD生物标志物,以改善早期检测和风险分层.
主要方法:
- 开发了AMD-Mamba,这是一个集色底图像,遗传变异和社会人口统计数据的多模式框架.
- 采用了一种新的度量学习策略,使用AMD严重程度尺度来实现更丰富的特征表示.
- 利用Vision Mamba将本地和全球图像信息融合在一起,增强了超越传统CNN的分析.
- 实现了多尺度的融合,将成像和临床变量结合在不同的分辨率.
主要成果:
- 拟议的AMD生物标志物证明了AMD进展的显著预测能力.
- 在与现有变量相结合时,AMD-Mamba在早期阶段可以更好地检测高风险的AMD患者.
- 对AREDS数据集的实验验证 (45,818张图像,52个遗传变异,3个来自2,741名受试者的社会人口学变量) 证实了框架的有效性.
结论:
- AMD-Mamba提供了一个有前途的多模式方法,用于更精确的AMD预后.
- 这种新生物标志物有助于识别患AMD进展高风险的个体.
- 这一框架为AMD患者提供了主动和个性化的管理策略.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21